Genomic Analysis Of The Novel Epigenetic Modifier Smchd1 As A Tumour Suppressor
Funder
National Health and Medical Research Council
Funding Amount
$619,142.00
Summary
Epigenetic modifications are changes made to our DNA that act like punctuation marks in the genome, to instruct the cell when to turn genes on and when to switch them off. Epigenetic control is critical to range of different biological processes, and also goes awry in cancer. We are specifically interested in the role of one new protein involved in epigentic control and characterising its role as a tumour suppressor.
Identification Of Novel Familial Patterns And Genotypes Associated With Inherited Risk In Adult-onset Sarcoma: The International Sarcoma Kindred Study
Funder
National Health and Medical Research Council
Funding Amount
$552,855.00
Summary
Inherited genetic risk is important in cancers that affect the young. The International Sarcoma Kindred Study (ISKS) is the world's first prospective study aiming to better understand how sarcomas can be inherited in families, and the genes that cause sarcomas. The ISKS is a multinational study led from Australia, with partners in the US, Europe and India, and aims to recruit over 3000 families affected by sarcoma.
HIC1 Prevents Tumour Initiation By Maintaining Genomic Stability
Funder
National Health and Medical Research Council
Funding Amount
$531,681.00
Summary
Chromosomes are large structures that package the genome. Abnormalities in the structure and function of chromosomes are now recognised an in important driver of cancer. Using a genetically engineered mouse model this project seeks to understand how this process evolves from the very earliest stages in the evolution of a tumour.
Determining The Origin Of Lethal Metastases In Multifocal Primary Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$696,470.00
Summary
New biomarkers are required to accurately predict lethal prostate cancer from benign, indolent disaese that doesn't require expensive treatment. To do this relies on finding molecular differences between disease states. Advancements in high throughput genomic technologies enables us to now probe the lethal prostate cancer genome and transcriptome and distinguish this disease state from other forms of prostate cancer.
Identification And Characterisation Of Novel FLT3-ITD Co-operating Mutations
Funder
National Health and Medical Research Council
Funding Amount
$659,245.00
Summary
Acute myeloid leukaemia is a cancer of the blood and bone marrow. We have identified new genes that act with the known oncogene FLT3-ITD in myeloid disease. We will examine in detail how these new genes contribute to the development of AML. This will aid in the development of new therapies for groups of AML patients with these mutations.
Novel Therapeutic Approaches To Ovarian Clear Cell Cancer
Funder
National Health and Medical Research Council
Funding Amount
$500,920.00
Summary
Our study aims to develop novel therapies for clear cell ovarian cancer, a disease that is generally resistant to conventional therapies. We have found unexpected parallels between kidney cancer and ovarian clear cell cancer, and this has been used to better treat patients. This study investigates the underlying molecular changes the control ovarian clear cell cancer growth.
A Genomic Approach Towards An Understanding Of Clonal Evolution And Disease Progression In Multiple Myeloma
Funder
National Health and Medical Research Council
Funding Amount
$671,689.00
Summary
Cancer development is associated with changes in the genetic composition of the cell. These changes involve the loss/gain of genetic material and/or changes in gene expression. Using sophisticated technology, we will define the changes in the genes that are associated with the transition from a benign to a malignant cancer state. We will examine this process in the blood cancer, multiple myeloma, in order to identify new treatment targets for this incurable disease.